Kymera Therapeutics (KYMR) CMO reports option exercise and stock sales

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. reported insider activity by its Chief Medical Officer, who filed a Form 4 for transactions in the company’s common stock on 12/08/2025.

The filing shows the officer exercised a stock option for 49,307 shares of common stock at an exercise price of $5.33 per share and, on the same date, sold common stock in multiple transactions with weighted average prices including $87.3711, $88.0215, $89.4264, $90.1226, $91.4639 and $92.19. These trades were effected under a Rule 10b5-1 trading plan dated June 2, 2025. After the transactions, the officer directly beneficially owned 109,992 shares of common stock and 34,083 stock options with a $5.33 exercise price.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gollob Jared

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/08/2025		M(1)		49,307	A	$5.33	159,299	D
Common Stock	12/08/2025		S(1)		13,759	D	$87.3711(2)	145,540	D
Common Stock	12/08/2025		S(1)		18,357	D	$88.0215(3)	127,183	D
Common Stock	12/08/2025		S(1)		3,929	D	$89.4264(4)	123,254	D
Common Stock	12/08/2025		S(1)		8,562	D	$90.1226(5)	114,692	D
Common Stock	12/08/2025		S(1)		3,300	D	$91.4639(6)	111,392	D
Common Stock	12/08/2025		S(1)		1,400	D	$92.19	109,992	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.33	12/08/2025		M(1)			49,307	(7)	05/13/2030	Common Stock	49,307	$0	34,083	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.77 to $87.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.77 to $88.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.87 to $89.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.905 to $90.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.04 to $92.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kymera Therapeutics (KYMR) report in this Form 4?

The Chief Medical Officer of Kymera Therapeutics, Inc. reported exercising a stock option for 49,307 shares of common stock at an exercise price of $5.33 per share and selling common stock in several open-market transactions on 12/08/2025.

When did the Kymera Therapeutics CMO’s reported trades occur?

The earliest transaction date disclosed is 12/08/2025, when the Chief Medical Officer both exercised stock options and sold Kymera Therapeutics common stock.

How many Kymera Therapeutics shares does the CMO own after these transactions?

Following the reported transactions, the Chief Medical Officer beneficially owned 109,992 shares of Kymera Therapeutics common stock directly.

What stock options does the Kymera Therapeutics CMO hold after the Form 4 trades?

After the transactions, the officer beneficially owned 34,083 derivative securities in the form of stock options, each with an exercise price of $5.33 per share and underlying Kymera Therapeutics common stock.

Were the Kymera Therapeutics CMO’s trades made under a Rule 10b5-1 plan?

Yes. The explanation states that these transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 that was adopted by the reporting person.

At what prices were Kymera Therapeutics shares sold in this Form 4?

The Form 4 reports weighted average sale prices including $87.3711, $88.0215, $89.4264, $90.1226, $91.4639 and $92.19 per share. Footnotes explain that each figure is a weighted average for multiple trades within specified price ranges.

What does the Form 4 say about the vesting of the Kymera Therapeutics stock options?

A footnote states that the shares underlying the reported stock option are fully vested and exercisable, meaning the officer may exercise those options in accordance with their terms.